Hydroxycarbamid

Phase 2Small molecule

TTheravia

Hydroxycarbamid is one of 74 small molecule programs targeting Retinal Vein Occlusion. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinal Vein OcclusionActive, not recruiting

Sickle Cell DiseaseActive, not recruiting

Retinal Vein OcclusionPhase 2

Active, not recruiting

Sickle Cell DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

272 competitors in Sickle Cell Disease

#DrugCompanyPhaseTrials

Adakveo

Novartis

Phase 3

7 2

Exjade

Novartis

Phase 3

4 3

Brilinta

AstraZeneca

Phase 3

3 4

Campath

GGenzyme, a Sanofi Company

Phase 3

12 5

Ritalin

Novartis

Phase 3

2 6

Cysteine Hydrochloride

Novartis

Phase 3

2 7

Eliquis

Bristol-Myers Squibb

Phase 3

1 8

Oxbryta

GGlobal Blood Therapeutics

Phase 3

5 9

Aqvesme

AAgios Pharmaceuticals, Inc.

Phase 3

4 10

Effient

CCosette Pharmaceuticals, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Sickle Cell Disease

NCT06578507

Clinical

Trials by Indication[1]

Sickle Cell Disease1 trial

Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease

Recruiting·TTheravia·Phase 2·NCT06578507·50 enrolled

Retinal Vein Occlusion1 trial

Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment.

Unknown status·—·Phase 2·NCT02957760·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Hydroxycarbamid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hydroxycarbamid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hydroxycarbamid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Theravia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTheravia

Hydroxycarbamid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Sickle Cell Disease1 trial

Retinal Vein Occlusion1 trial

References

Drug Info

Quick Facts

Related News